R&D Trends

RXi Pharmaceuticals, Hapten Pharmaceuticals ink agreement

Friday, December 19, 2014 12:05 PM

RXi Pharmaceuticals, a Marlborough, Mass.,-based biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, has entered into an assignment and exclusive global license agreement with Hapten Pharmaceuticals, an early stage dermatology product development company based in New York, for the therapeutic use of Samcyprone.

More... »

Sorrento, Conkwest collaborate for cancer immunotherapies

Friday, December 19, 2014 12:03 PM

Sorrento Therapeutics, an oncology company based in San Diego, Calif., and Conkwest, a Cardiff-by-the-Sea, Calif.-based, privately-held immuno-oncology company developing proprietary Neukoplast (NK-92), a natural killer cell-line based therapy, have entered into a definitive agreement to jointly develop next generation CAR-TNK immunotherapies for the treatment of cancer.

More... »


Lilly, Adocia ink alliance for ultra-rapid insulin based on BioChaperone

Friday, December 19, 2014 12:02 PM

Eli Lilly and Adocia, a France-based clinical-stage biotechnology company, have announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. BioChaperone Lispro relies on Adocia's proprietary BioChaperone technology and currently is in phase Ib studies.

More... »

Report: Top 30 pharma companies spent $112B on R&D in 2013

Thursday, December 18, 2014 11:19 AM

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on R&D in 2013, an increase of $723 million over the previous year, according to London-based research and consulting firm GlobalData.

More... »

Curie-Cancer, GamaMabs Pharma renew research partnership

Wednesday, December 17, 2014 12:17 PM

Curie-Cancer, the Paris-based body responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a French biotechnology company developing monoclonal antibodies for cancer, have extended their partnership to develop the 3C23K antibody for the treatment of gynecological cancers.

More... »

OPKO, Pfizer ink global agreement for human growth hormone

Monday, December 15, 2014 12:39 PM

OPKO Health, a multinational biopharmaceutical and diagnostics company, and Pfizer have entered into a worldwide agreement for the development and commercialization of OPKO's long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by two years of age.

More... »

Congress includes $25 million increase for Alzheimer’s research funding in spending bill

Monday, December 15, 2014 12:33 PM

The 2015 U.S. government spending package, known as the cromnibus, includes an increase of $25 million for the National Institute on Aging (NIA), with an expectation that much of the funding would support additional research into Alzheimer’s and dementia.

More... »

Janssen Therapeutics, USAID collaborate on antimicrobial resistance

Monday, December 15, 2014 12:32 PM

Janssen Therapeutics, a Johnson & Johnson affiliate, has signed a memorandum of understanding (MOU) with the U.S. Agency for International Development (USAID) to step up the fight against the health threat of antibiotic-resistant bacteria.

More... »

ALS Association awards research funds for C9orf72 clinical trials

Friday, December 12, 2014 03:34 PM

The ALS Association, a national nonprofit organization based in Wash. D.C., has awarded $326,662 in research funds to expand ongoing natural history studies in order to further understand the most common genetic cause of ALS, in preparation for clinical trials in those whose disease is affected by this gene.

More... »

Senators introduce bill for streamlined pathway to approval for antibiotics

Friday, December 12, 2014 03:33 PM

U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT) have introduced a bill to create a new drug approval pathway to streamline access and encourage innovation and development of potentially lifesaving antibiotic drugs for patients, particularly Veterans who have encountered antibiotic-resistant bacteria while overseas.

More... »

Link to survey



Browse by:


December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs